Skip to main content

Most Popular in News

Most Recent

FDA approval stamp | Widaplik for hypertension

Widaplik for hypertension

It’s a new triple combination medication to treat high blood pressure
A tablet with charts on it: Statin statistics

Statin statistics 2025

How many people are taking statins, how much we spend on these cholesterol-lowering drugs, and more
A tablet with charts on it: Insulin statistics

Insulin statistics 2025

How many people rely on insulin around the world, how insulin prices have changed, and more
Three mobile devices with charts on them: Fentanyl facts and statistics

Fentanyl facts and statistics

Current fentanyl stats, overdose facts, and why it’s so dangerous when misused
A chart on a clipboard: Ozempic statistics

Ozempic statistics 2025

How many people are using Ozempic in 2025?
FDA approves generic Xarelto

FDA approves generic Xarelto

There’s a new—hopefully, lower cost—option for people who take anticoagulants to manage heart disease
FDA stamp - Merilog

FDA approves rapid-acting insulin biosimilar

Merilog works like NovoLog to help control blood sugar when injected five to ten minutes before meals
An FDA approval stamp for the approval of Ozempic and kidney function

Ozempic for kidney disease

This diabetes medication is now indicated to prevent the worsening of kidney disease, kidney failure, and death due to cardiovascular disease
victoza generic - FDA approval

FDA approves first generic once-daily GLP-1

Liraglutide, the generic of Victoza, is now available to treat Type 2 diabetes, alongside diet and exercise
Zepbound obstructive sleep apnea - FDA stamp

Zepbound for sleep apnea

It’s the first medication that reduces symptom severity, reducing breathing interruptions at night
FDA stamp - FDA warning compounded semaglutide

FDA issues warning to GLP-1 compounders

The U.S. Food and Drug Administration is sounding the alarm about the risks of taking unapproved versions of Ozempic, Wegovy, Zepbound, and Mounjaro
1 2 3 18